Abstract
Prenatal, perinatal, and postnatal factors have been shown to shape neurobiological functioning and alter the risk for mental disorders later in life. The gut microbiome is established early in life, and interacts with the brain via the brain-immune-gut axis. However, little is known about how the microbiome relates to early-life cognitive functioning in children. The present study, where the fecal microbiome of 380 children was characterized using 16s rDNA and metagenomic sequencing aimed to investigate the association between the microbiota and cognitive functioning of children at the age of 45 months measured with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III).
Overall the microbiome profile showed a significant association with cognitive functioning. A strong correlation was found between cognitive functioning and the relative abundance of an unidentified genus of the family Enterobacteriaceae. Follow-up mediation analyses revealed significant mediation effects of the level of this genus on the association of maternal smoking during pregnancy and current cigarette smoking with cognitive function. Metagenomic sequencing of a subset of these samples indicated that the identified genus was most closely related to Enterobacter asburiae. Analysis of metabolic potential showed a nominally significant association of cognitive functioning with the microbial norspermidine biosynthesis pathway.
Our results indicate that alteration of the gut microflora is associated with cognitive functioning in childhood. Furthermore, they suggest that the altered microflora might interact with other environmental factors such as maternal cigarette smoking. Interventions directed at altering the microbiome should be explored in terms of improving cognitive functioning in young children.
Competing Interest Statement
Michael Deuschle participated as principal investigator in studies of Johnson & Johnson and received speaker fees of AbbVie. The other authors report no biomedical financial interests or potential conflicts of interest.
Clinical Trial
DRKS00006338
Funding Statement
This study was supported by: Stanley Medical Research Institute. National Institute of Mental Health (P50) Silvio O Conte Center at Johns Hopkins. ERA-NET NEURON grants EMBED (01EW1904), and SynSchiz-Linking synaptic dysfunction to disease mechanisms in schizophrenia-a multilevel investigation (01EW1810 to MR). German Research Foundation grants RI908/11-2 and WI3439/3-2.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Medical Faculty Mannheim of the University of Heidelberg.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated analysis: Metagenomic pathways added Covariates added to REML models BMI added as covariates Exploration of effects of perceived stress variables Updated discussion. Language editing
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to privacy regulations but are available from the authors on reasonable request.